Thalidomide Influences Growth and Vasculogenic Mimicry Channel Formation in Melanoma

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2008 Nov 6

PMID 18983651

Citations 38

Authors

Shiwu Zhang

Man Li

Yanjun Gu

Zhiyong Liu

Shaoyan Xu

Yanfeng Cui

Baocun Sun

Affiliations

Soon will be listed here.

Abstract

Aims: To observe the effects of thalidomide on melanoma tumor growth and blood supply patterns in C57 mice.

Methods: Thirty mice inoculated subcutaneously with B16F10 cells were randomly divided into the treatment group and the control group. Thalidomide was administered once a day at a dose of 200 mg/kg for the treatment group starting on the fifth day after inoculation, and an equivalent volume of 0.5% carboxylmethyl cellulose was administered similarly in the control group. The diameter of the tumors was measured daily after inoculation until the mice were sacrificed on the 19th day. The different blood supply patterns were counted after immunohistochemical and PAS histochemical double-Staining. VEGF, NF-kappaB, PCNA, MMP-2 and MMP-9 expression in tumor tissue was also assessed.

Results: The tumor volume(P = 0.019) and the number of vasculogenic mimicry(P = 0.03) and mosaic vessels(P = 0.004) in the treatment group were significantly decreased compared with the control group. VEGF(P = 0.004), NF-kappaB(P = 0.009), PCNA(P = 0.002), MMP-2 (P = 0.000), MMP-9(P = 0.002) protein expression and MMP-2(P = 0.000) and MMP-9(P = 0.000) mRNA in the treatment group were significantly lower than those in the control groups.

Conclusion: Thalidomide inhibits vasculogenic mimicry channel and mosaic vessels formation in melanoma through the regulation of vasculogenic factors, and it can induce necrosis of melanoma cells, which may be related with the NF-kappaB signaling pathway.

Citing Articles

Advance in vasculogenic mimicry in ovarian cancer (Review).

Tian X, Si Q, Liu M, Shi J, Zhao R, Xiong Y Oncol Lett. 2023; 26(4):456.

PMID: 37736556 PMC: 10509778. DOI: 10.3892/ol.2023.14043.

Vandetanib alters the tumoricidal capacity of human breast cancer stem cells via inhibiting vasculogenic capacity.

Haiaty S, Rashidi M, Akbarzadeh M, Bazmany A, Mostafazadeh M, Nikanfar S Bioimpacts. 2023; 13(5):405-413.

PMID: 37736340 PMC: 10509738. DOI: 10.34172/bi.2022.24208.

Cancer apelin receptor suppresses vascular mimicry in malignant melanoma.

Inukai K, Kise K, Hayashi Y, Jia W, Muramatsu F, Okamoto N Pathol Oncol Res. 2023; 29:1610867.

PMID: 36776217 PMC: 9912982. DOI: 10.3389/pore.2023.1610867.

New Peptide-Drug Conjugates for Precise Targeting of SORT1-Mediated Vasculogenic Mimicry in the Tumor Microenvironment of TNBC-Derived MDA-MB-231 Breast and Ovarian ES-2 Clear Cell Carcinoma Cells.

Charfi C, Demeule M, Currie J, Larocque A, Zgheib A, Danalache B Front Oncol. 2021; 11:760787.

PMID: 34751242 PMC: 8571021. DOI: 10.3389/fonc.2021.760787.

Thalidomide Suppresses Angiogenesis Through the Signal Transducer and Activator of Transcription 3/SP4 Signaling Pathway in the Peritoneal Membrane.

Zhu N, Wang L, Guo H, Jia J, Gu L, Wang X Front Physiol. 2021; 12:712147.

PMID: 34539435 PMC: 8446434. DOI: 10.3389/fphys.2021.712147.

References

Ishizaki T, Katsumata K, Tsuchida A, Wada T, Mori Y, Hisada M . Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. Int J Mol Med. 2006; 17(2):357-62. View

Son M, Kim J, Kim M, Song H, Kim J, Kim H . Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. Int J Oncol. 2005; 28(1):53-9. View

Getmanova E, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V . Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol. 2006; 13(5):549-56. DOI: 10.1016/j.chembiol.2005.12.009. View

Sun B, Zhang S, Zhang D, Du J, Guo H, Zhao X . Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep. 2006; 16(4):693-8. View

Zhang S, Zhang D, Wang Y, Zhao W, Guo H, Zhao X . Morphologic research of microcirculation patterns in human and animal melanoma. Med Oncol. 2006; 23(3):403-9. DOI: 10.1385/MO:23:3:403. View

Kirchmair R, Tietz A, Panagiotou E, Walter D, Silver M, Yoon Y . Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF. Mol Ther. 2006; 15(1):69-75. DOI: 10.1038/sj.mt.6300019. View

Basu G, Liang W, Stephan D, Wegener L, Conley C, Pockaj B . A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Res. 2006; 8(6):R69. PMC: 1797025. DOI: 10.1186/bcr1626. View

Knobloch J, Shaughnessy Jr J, Ruther U . Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J. 2007; 21(7):1410-21. DOI: 10.1096/fj.06-7603com. View

Zhang S, Zhang D, Sun B . Vasculogenic mimicry: current status and future prospects. Cancer Lett. 2007; 254(2):157-64. DOI: 10.1016/j.canlet.2006.12.036. View

10.

Stein E, Rivera C . Transient thyroiditis after treatment with lenalidomide in a patient with metastatic renal cell carcinoma. Thyroid. 2007; 17(7):681-3. DOI: 10.1089/thy.2006.0294. View

11.

McMeekin D, Sill M, Darcy K, Stearns-Kurosawa D, Webster K, Waggoner S . A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol. 2007; 106(3):596-603. DOI: 10.1016/j.ygyno.2007.05.013. View

12.

de-Blanco E, Pandit B, Hu Z, Shi J, Lewis A, Li P . Inhibitors of NF-kappaB derived from thalidomide. Bioorg Med Chem Lett. 2007; 17(21):6031-5. DOI: 10.1016/j.bmcl.2007.01.088. View

13.

Aerbajinai W, Zhu J, Gao Z, Chin K, Rodgers G . Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood. 2007; 110(8):2864-71. PMC: 2018668. DOI: 10.1182/blood-2007-01-065201. View

14.

Sun B, Zhang S, Zhang D, Yin X, Wang S, Gu Y . Doxycycline influences microcirculation patterns in B16 melanoma. Exp Biol Med (Maywood). 2007; 232(10):1300-7. DOI: 10.3181/0705-RM-145. View

15.

Yau T, Chan P, Wong H, Ng K, Chok S, Cheung T . Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology. 2007; 72 Suppl 1:67-71. DOI: 10.1159/000111709. View

16.

Sun B, Qie S, Zhang S, Sun T, Zhao X, Gao S . Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum Pathol. 2008; 39(3):444-51. DOI: 10.1016/j.humpath.2007.07.018. View

17.

Kale R, Tayade P, Saraf M, Juvekar A . Molecular encapsulation of thalidomide with sulfobutyl ether-7 beta-cyclodextrin for immediate release property: enhanced in vivo antitumor and antiangiogenesis efficacy in mice. Drug Dev Ind Pharm. 2008; 34(2):149-56. DOI: 10.1080/03639040701484486. View

18.

Su M, Feng Y, Yao L, Cheng M, Xu C, Huang Y . Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo. Int J Gynecol Cancer. 2007; 18(3):476-86. DOI: 10.1111/j.1525-1438.2007.01034.x. View

19.

Shannon E, Noveck R, Sandoval F, Kamath B . Thalidomide suppressed IL-1beta while enhancing TNF-alpha and IL-10, when cells in whole blood were stimulated with lipopolysaccharide. Immunopharmacol Immunotoxicol. 2008; 30(3):447-57. DOI: 10.1080/08923970802135161. View

20.

Matsuda K, Madoiwa S, Hasumi Y, Kanazawa T, Saga Y, Kume A . A novel strategy for the tumor angiogenesis-targeted gene therapy: generation of angiostatin from endogenous plasminogen by protease gene transfer. Cancer Gene Ther. 2000; 7(4):589-96. DOI: 10.1038/sj.cgt.7700147. View